Avera Health to lead new clinical trial for non-small cell lung cancer patients

Our friends at Avera Health will lead a new clinical trial for non-small cell lung cancer patients.

As a world leader in precision medicine dedicated to improving outcomes in patients with cancer, they will be the first to enroll patients in the Survival Prolongation by Rationale Innovative Genomics (SPRING) trial.

Patients will receive a three-drug protocol that incorporates immunotherapy and two targeted therapies. The FDA approved trial is Avera’s latest collaboration as part its membership in the Worldwide Innovative Networking (WIN) Consortium.